Brokerages Set Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Price Target at $21.75

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has earned a consensus rating of “Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $21.33.

Several brokerages recently weighed in on VNDA. BidaskClub cut shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. Oppenheimer Holdings, Inc. set a $21.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Piper Jaffray Companies set a $23.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. HC Wainwright set a $18.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, Jefferies Group LLC reissued a “buy” rating and set a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, May 25th.

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded up 0.32% on Friday, reaching $15.45. 63,241 shares of the company traded hands. Vanda Pharmaceuticals has a 1-year low of $11.58 and a 1-year high of $18.00. The firm’s market capitalization is $693.06 million. The stock has a 50-day moving average price of $16.17 and a 200 day moving average price of $14.69.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.18. The firm had revenue of $42.06 million for the quarter, compared to analysts’ expectations of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The firm’s revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.01 earnings per share. Analysts anticipate that Vanda Pharmaceuticals will post ($0.52) EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. Legal & General Group Plc raised its position in Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 3,022 shares during the period. Virginia Retirement Systems ET AL purchased a new position in Vanda Pharmaceuticals during the first quarter worth $193,000. Capital Fund Management S.A. purchased a new position in Vanda Pharmaceuticals during the first quarter worth $195,000. Dynamic Technology Lab Private Ltd purchased a new position in Vanda Pharmaceuticals during the first quarter worth $196,000. Finally, AQR Capital Management LLC purchased a new position in Vanda Pharmaceuticals during the fourth quarter worth $223,000. Institutional investors and hedge funds own 91.42% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Brokerages Set Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Price Target at $21.75” was first posted by BNB Daily and is the property of of BNB Daily. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/analysts-set-vanda-pharmaceuticals-inc-nasdaqvnda-price-target-at-21-75-updated-updated-updated.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply